Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis

Takafumi Toyohara, Filip Roudnicky, Mary H.C. Florido, Toshiaki Nakano, Haojie Yu, Shunsuke Katsuki, Minjin Lee, Torsten Meissner, Max Friesen, Lance S. Davidow, Leon Ptaszek, Takaaki Abe, Lee L. Rubin, Alexandre C. Pereira, Masanori Aikawa, Chad A. Cowan

研究成果: Article査読

4 被引用数 (Scopus)

抄録

Why some patients with type 2 diabetes are protected against cardiovascular disease (CVD) has not been clarified. Toyohara et al. reveal that in patients protected from CVD, arylacetamide deacetylase (AADAC) is elevated in vascular smooth muscle cells (VSMCs). AADAC alters lipid metabolism and cellular processes in VSMCs and ameliorates CVD.

本文言語English
ページ(範囲)147-157.e7
ジャーナルCell Stem Cell
27
1
DOI
出版ステータスPublished - 2020 7 2

ASJC Scopus subject areas

  • 分子医療
  • 遺伝学
  • 細胞生物学

フィンガープリント

「Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル